These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 27455511)

  • 21. Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?
    Papadaki S; Tselepis AD
    Angiology; 2019 Nov; 70(10):896-907. PubMed ID: 31010298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Demeanor of rivaroxaban in activated/inactivated FXa.
    Seki K; Mizuno Y; Sakashita T; Nakano S; Tanno J; Okazaki Y; Muramatsu T; Nishimura S; Senbonmatsu T
    J Pharmacol Sci; 2017 Mar; 133(3):156-161. PubMed ID: 28314697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review.
    Khadse AN; Sharma MK; Murumkar PR; Rajput SJ; Yadav MR
    Mini Rev Med Chem; 2018; 18(16):1332-1353. PubMed ID: 29692238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro.
    Bunce MW; Toso R; Camire RM
    Blood; 2011 Jan; 117(1):290-8. PubMed ID: 20864578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.
    Sartori M; Cosmi B
    J Thromb Thrombolysis; 2018 Apr; 45(3):345-352. PubMed ID: 29372400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Andexanet Alfa (Andexxa) Formulary Review.
    Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
    Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.
    Ghadimi K; Dombrowski KE; Levy JH; Welsby IJ
    Expert Rev Hematol; 2016; 9(2):115-22. PubMed ID: 26686866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surfing the Blood Coagulation Cascade: Insight into the Vital Factor Xa.
    Núñez-Navarro NE; Santana FM; Parra LP; Zacconi FC
    Curr Med Chem; 2019; 26(17):3175-3200. PubMed ID: 29376487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
    Honda Y; Kamisato C; Morishima Y
    Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
    Sun X; Hong Z; Liu M; Guo S; Yang D; Wang Y; Lan T; Gao L; Qi H; Gong P; Liu Y
    Bioorg Med Chem; 2017 May; 25(10):2800-2810. PubMed ID: 28389110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
    Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
    Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era.
    Rühl H; Reda S; Müller J; Oldenburg J; Pötzsch B
    Thromb Haemost; 2018 Feb; 118(2):381-387. PubMed ID: 29378360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays.
    Aungraheeta R; FitzGibbon L; Reilly-Stitt C; Mumford AD
    Int J Lab Hematol; 2020 Apr; 42(2):126-133. PubMed ID: 31756037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of AcAP5 as a novel factor Xa inhibitor with both direct and allosteric inhibition.
    Zhu Y; Lin Y; Liu X; Hu W; Wang Y
    Biochem Biophys Res Commun; 2017 Jan; 483(1):495-501. PubMed ID: 28007598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors.
    Huang C; Wang W; Li Y; Zhang S; Meng F; Xu W; Yuan J; Chen L
    Oncotarget; 2017 Jun; 8(23):37186-37199. PubMed ID: 28415603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding.
    Jankowski W; Surov SS; Hernandez NE; Rawal A; Battistel M; Freedberg D; Ovanesov MV; Sauna ZE
    Nat Commun; 2024 May; 15(1):3912. PubMed ID: 38724509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity.
    Ivanciu L; Camire RM
    Blood; 2015 Jul; 126(1):94-102. PubMed ID: 25896653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data.
    Terayama Y
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1171-1181. PubMed ID: 28169097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Concepts in anticoagulant therapy - past, present, and future].
    Graf L
    Ther Umsch; 2012 Nov; 69(11):611-5. PubMed ID: 23117663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.